Open AccessPreclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
Author(s) -
Ning Zhang,
Changqing Zhang,
Zhihong Zeng,
Jiyong Zhang,
Shanshan Du,
Chunde Bao,
Zhe Wang
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s301076
Subject(s) - rheumatoid arthritis , medicine , pharmacology , arthritis , adverse effect , tofacitinib , toxicity , adjuvant , immunology
Research on JAK family members as therapeutic targets for autoimmune diseases has brought tofacitinib and baricitinib into clinical for the treatment of rheumatoid arthritis and other autoimmune diseases. Despite the potent efficacy of these first-generation JAK inhibitors, their broad-spectrum JAK inhibition and adverse events warrant development of a JAK1-specific inhibitor to improve their safety profile.